Chikungunya Fever Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Diagnosis (ELISA Based Assays, Serological Tests, Virological Tests), By Treatment (Allopathy, Homeopathy, Ayurveda, Others), By End User (Hospital & Clinics, Ambulatory Surgical care, Others), By Region and Competition, 2020-2030F

December 2025 | 185 pages | ID: CE8B0CFB2D61EN
TechSci Research

Abstracts

The Global Chikungunya Fever Market, valued at USD 493.23 Million in 2024, is projected to experience a CAGR of 7.28% to reach USD 751.91 Million by 2030. The Global Chikungunya Fever Market encompasses therapeutic interventions, diagnostic solutions, and preventive measures addressing this mosquito-borne viral infection, primarily transmitted by *Aedes aegypti* and *Aedes albopictus* mosquitoes.

Key Market Drivers

The rising global incidence of Chikungunya Fever significantly drives market demand for diagnostic tools, therapeutic interventions, and preventive vaccines. Heightened disease prevalence necessitates more widespread testing and treatment, accelerating product development. According to the European Centre for Disease Prevention and Control, as of November 2024, approximately 480,000 Chikungunya cases were reported worldwide, underscoring the expanding public health challenge.

Key Market Challenges

The persistent gap in surveillance capabilities and diagnostic readiness represents a significant impediment to the growth of the Global Chikungunya Fever Market. This challenge directly hampers the market by delaying timely detection and effective management of the disease, thereby limiting the demand for diagnostic solutions and subsequent therapeutic interventions. When infections go undetected or are misdiagnosed, the market for related products cannot expand to its full potential.

Key Market Trends

Advances in mRNA Vaccine Technology represent a pivotal trend, expediting the development cycle for Chikungunya vaccines by enabling rapid antigen identification and flexible manufacturing processes. This technology allows for quicker responses to emerging viral strains and offers the potential for high-efficacy profiles. According to *Vaccine*, in June 2023, Moderna's mRNA-1388 Chikungunya vaccine candidate demonstrated favorable safety and immunogenicity in a Phase 1 study, eliciting substantial and persistent neutralizing antibody responses in healthy adults.

Key Market Players

• Quest Diagnostics, Inc.
• Abbott Laboratories, Inc.
• Genome Diagnostics Pvt. Ltd.
• Altona Diagnostics GmbH
• Bio-Rad Laboratories, Inc.
• Taj Pharmaceuticals Ltd.
• Etubics Corporation
• Shanghai Solve Care Co. Ltd.

Report Scope:

In this report, the Global Chikungunya Fever Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Chikungunya Fever Market, By Diagnosis:
• ELISA Based Assays
• Serological Tests
• Virological Tests
• Chikungunya Fever Market, By Treatment:
• Allopathy
• Homeopathy
• Ayurveda
• Others
• Chikungunya Fever Market, By End User:
• Hospital & Clinics
• Ambulatory Surgical care
• Others
• Chikungunya Fever Market, By Region:
• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Chikungunya Fever Market.

Available Customizations:

Global Chikungunya Fever Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Contents

1. PRODUCT OVERVIEW

1.1. Market Definition
1.2. Scope of the Market
  1.2.1. Markets Covered
  1.2.2. Years Considered for Study
  1.2.3. Key Market Segmentations

2. RESEARCH METHODOLOGY

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. EXECUTIVE SUMMARY

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. VOICE OF CUSTOMER

5. GLOBAL CHIKUNGUNYA FEVER MARKET OUTLOOK

5.1. Market Size & Forecast
  5.1.1. By Value
5.2. Market Share & Forecast
  5.2.1. By Diagnosis (ELISA Based Assays, Serological Tests, Virological Tests)
  5.2.2. By Treatment (Allopathy, Homeopathy, Ayurveda, Others)
  5.2.3. By End User (Hospital & Clinics, Ambulatory Surgical care, Others)
  5.2.4. By Region
  5.2.5. By Company (2024)
5.3. Market Map

6. NORTH AMERICA CHIKUNGUNYA FEVER MARKET OUTLOOK

6.1. Market Size & Forecast
  6.1.1. By Value
6.2. Market Share & Forecast
  6.2.1. By Diagnosis
  6.2.2. By Treatment
  6.2.3. By End User
  6.2.4. By Country
6.3. North America: Country Analysis
  6.3.1. United States Chikungunya Fever Market Outlook
    6.3.1.1. Market Size & Forecast
      6.3.1.1.1. By Value
    6.3.1.2. Market Share & Forecast
      6.3.1.2.1. By Diagnosis
      6.3.1.2.2. By Treatment
      6.3.1.2.3. By End User
  6.3.2. Canada Chikungunya Fever Market Outlook
    6.3.2.1. Market Size & Forecast
      6.3.2.1.1. By Value
    6.3.2.2. Market Share & Forecast
      6.3.2.2.1. By Diagnosis
      6.3.2.2.2. By Treatment
      6.3.2.2.3. By End User
  6.3.3. Mexico Chikungunya Fever Market Outlook
    6.3.3.1. Market Size & Forecast
      6.3.3.1.1. By Value
    6.3.3.2. Market Share & Forecast
      6.3.3.2.1. By Diagnosis
      6.3.3.2.2. By Treatment
      6.3.3.2.3. By End User

7. EUROPE CHIKUNGUNYA FEVER MARKET OUTLOOK

7.1. Market Size & Forecast
  7.1.1. By Value
7.2. Market Share & Forecast
  7.2.1. By Diagnosis
  7.2.2. By Treatment
  7.2.3. By End User
  7.2.4. By Country
7.3. Europe: Country Analysis
  7.3.1. Germany Chikungunya Fever Market Outlook
    7.3.1.1. Market Size & Forecast
      7.3.1.1.1. By Value
    7.3.1.2. Market Share & Forecast
      7.3.1.2.1. By Diagnosis
      7.3.1.2.2. By Treatment
      7.3.1.2.3. By End User
  7.3.2. France Chikungunya Fever Market Outlook
    7.3.2.1. Market Size & Forecast
      7.3.2.1.1. By Value
    7.3.2.2. Market Share & Forecast
      7.3.2.2.1. By Diagnosis
      7.3.2.2.2. By Treatment
      7.3.2.2.3. By End User
  7.3.3. United Kingdom Chikungunya Fever Market Outlook
    7.3.3.1. Market Size & Forecast
      7.3.3.1.1. By Value
    7.3.3.2. Market Share & Forecast
      7.3.3.2.1. By Diagnosis
      7.3.3.2.2. By Treatment
      7.3.3.2.3. By End User
  7.3.4. Italy Chikungunya Fever Market Outlook
    7.3.4.1. Market Size & Forecast
      7.3.4.1.1. By Value
    7.3.4.2. Market Share & Forecast
      7.3.4.2.1. By Diagnosis
      7.3.4.2.2. By Treatment
      7.3.4.2.3. By End User
  7.3.5. Spain Chikungunya Fever Market Outlook
    7.3.5.1. Market Size & Forecast
      7.3.5.1.1. By Value
    7.3.5.2. Market Share & Forecast
      7.3.5.2.1. By Diagnosis
      7.3.5.2.2. By Treatment
      7.3.5.2.3. By End User

8. ASIA PACIFIC CHIKUNGUNYA FEVER MARKET OUTLOOK

8.1. Market Size & Forecast
  8.1.1. By Value
8.2. Market Share & Forecast
  8.2.1. By Diagnosis
  8.2.2. By Treatment
  8.2.3. By End User
  8.2.4. By Country
8.3. Asia Pacific: Country Analysis
  8.3.1. China Chikungunya Fever Market Outlook
    8.3.1.1. Market Size & Forecast
      8.3.1.1.1. By Value
    8.3.1.2. Market Share & Forecast
      8.3.1.2.1. By Diagnosis
      8.3.1.2.2. By Treatment
      8.3.1.2.3. By End User
  8.3.2. India Chikungunya Fever Market Outlook
    8.3.2.1. Market Size & Forecast
      8.3.2.1.1. By Value
    8.3.2.2. Market Share & Forecast
      8.3.2.2.1. By Diagnosis
      8.3.2.2.2. By Treatment
      8.3.2.2.3. By End User
  8.3.3. Japan Chikungunya Fever Market Outlook
    8.3.3.1. Market Size & Forecast
      8.3.3.1.1. By Value
    8.3.3.2. Market Share & Forecast
      8.3.3.2.1. By Diagnosis
      8.3.3.2.2. By Treatment
      8.3.3.2.3. By End User
  8.3.4. South Korea Chikungunya Fever Market Outlook
    8.3.4.1. Market Size & Forecast
      8.3.4.1.1. By Value
    8.3.4.2. Market Share & Forecast
      8.3.4.2.1. By Diagnosis
      8.3.4.2.2. By Treatment
      8.3.4.2.3. By End User
  8.3.5. Australia Chikungunya Fever Market Outlook
    8.3.5.1. Market Size & Forecast
      8.3.5.1.1. By Value
    8.3.5.2. Market Share & Forecast
      8.3.5.2.1. By Diagnosis
      8.3.5.2.2. By Treatment
      8.3.5.2.3. By End User

9. MIDDLE EAST & AFRICA CHIKUNGUNYA FEVER MARKET OUTLOOK

9.1. Market Size & Forecast
  9.1.1. By Value
9.2. Market Share & Forecast
  9.2.1. By Diagnosis
  9.2.2. By Treatment
  9.2.3. By End User
  9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
  9.3.1. Saudi Arabia Chikungunya Fever Market Outlook
    9.3.1.1. Market Size & Forecast
      9.3.1.1.1. By Value
    9.3.1.2. Market Share & Forecast
      9.3.1.2.1. By Diagnosis
      9.3.1.2.2. By Treatment
      9.3.1.2.3. By End User
  9.3.2. UAE Chikungunya Fever Market Outlook
    9.3.2.1. Market Size & Forecast
      9.3.2.1.1. By Value
    9.3.2.2. Market Share & Forecast
      9.3.2.2.1. By Diagnosis
      9.3.2.2.2. By Treatment
      9.3.2.2.3. By End User
  9.3.3. South Africa Chikungunya Fever Market Outlook
    9.3.3.1. Market Size & Forecast
      9.3.3.1.1. By Value
    9.3.3.2. Market Share & Forecast
      9.3.3.2.1. By Diagnosis
      9.3.3.2.2. By Treatment
      9.3.3.2.3. By End User

10. SOUTH AMERICA CHIKUNGUNYA FEVER MARKET OUTLOOK

10.1. Market Size & Forecast
  10.1.1. By Value
10.2. Market Share & Forecast
  10.2.1. By Diagnosis
  10.2.2. By Treatment
  10.2.3. By End User
  10.2.4. By Country
10.3. South America: Country Analysis
  10.3.1. Brazil Chikungunya Fever Market Outlook
    10.3.1.1. Market Size & Forecast
      10.3.1.1.1. By Value
    10.3.1.2. Market Share & Forecast
      10.3.1.2.1. By Diagnosis
      10.3.1.2.2. By Treatment
      10.3.1.2.3. By End User
  10.3.2. Colombia Chikungunya Fever Market Outlook
    10.3.2.1. Market Size & Forecast
      10.3.2.1.1. By Value
    10.3.2.2. Market Share & Forecast
      10.3.2.2.1. By Diagnosis
      10.3.2.2.2. By Treatment
      10.3.2.2.3. By End User
  10.3.3. Argentina Chikungunya Fever Market Outlook
    10.3.3.1. Market Size & Forecast
      10.3.3.1.1. By Value
    10.3.3.2. Market Share & Forecast
      10.3.3.2.1. By Diagnosis
      10.3.3.2.2. By Treatment
      10.3.3.2.3. By End User

11. MARKET DYNAMICS

11.1. Drivers
11.2. Challenges

12. MARKET TRENDS & DEVELOPMENTS

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. GLOBAL CHIKUNGUNYA FEVER MARKET: SWOT ANALYSIS

14. PORTER'S FIVE FORCES ANALYSIS

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. COMPETITIVE LANDSCAPE

15.1. Quest Diagnostics, Inc.
  15.1.1. Business Overview
  15.1.2. Products & Services
  15.1.3. Recent Developments
  15.1.4. Key Personnel
  15.1.5. SWOT Analysis
15.2. Abbott Laboratories, Inc.
15.3. Genome Diagnostics Pvt. Ltd.
15.4. Altona Diagnostics GmbH
15.5. Bio-Rad Laboratories, Inc.
15.6. Taj Pharmaceuticals Ltd.
15.7. Etubics Corporation
15.8. Shanghai Solve Care Co. Ltd.

16. STRATEGIC RECOMMENDATIONS

17. ABOUT US & DISCLAIMER